DDInter833 DDInter1658
Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Glycerol phenylbutyrate {u} (Compound) resembles {v} (Compound) Alverine
Glycerol phenylbutyrate {u} (Compound) binds {v} (Gene) PNLIP
Glycerol phenylbutyrate {u} (Compound) causes {v} (Side Effect) Asthenia
Glycerol phenylbutyrate (Compound) resembles Alverine (Compound)
Glycerol phenylbutyrate (Compound) binds PNLIP (Gene)
Glycerol phenylbutyrate (Compound) causes Asthenia (Side Effect)